100

Biotech runway is not cash, it is milestone math

Biotech runway is not just a cash balance. In these filings, it turns on whether the next milestone lands on time: Phase 3 data, BLA approval, launch, and access to financing that only opens after those events[[cite:1]][[cite:2]].

  • annual report cover 768x1086
🧵 1/5

Compass Pathways says its 2024 reorganisation was meant to preserve cash runway because trial timelines changed and extra spend was needed to finish Phase 3. It expects top-line COMP005 data in Q2 2025 and COMP006 data in 2H 2026[[cite:3]][[cite:4]][[cite:5]].

🧵 2/5

That means runway at Compass is really a timing bridge to the next readout and, if approved, to launch. The company says U.S. commercialization depends on regulatory approval, with third-party partnerships used in some non-U.S. markets[[cite:6]][[cite:7]].

🧵 3/5

Mesoblast is the same story in a different stage. It said cash should cover 12 months, but that coverage explicitly included the BLA process for remestemcel-L, and if it gets first approval and launches within 12 months it can access existing loan funds[[cite:8]][[cite:9]].

🧵 4/5

If approval or launch slips, Mesoblast says it may need strategic partnerships, product-specific financing, debt, or equity. Its debt facilities also impose cash covenants and default risk, and the filing says this uncertainty creates a material going-concern issue[[cite:10]][[cite:11]][[cite:12]][[cite:13]].

🧵 5/5

Related Content From The Pandipedia